Nature Communications Study by Amelia Haj and Colleagues Identifies Factor XII as a Safer Target for Anticoagulation
Broad Institute of MIT and Harvard shared on LinkedIn:
”Patients diagnosed with life-threatening blood clots known as venous thromboembolisms (VTEs) are treated with anticoagulants, but these drugs increase their risk of bleeding.
In Nature Communications, Amelia Haj, Patrick Ellinor, Pavan Bendapudi, and collaborators make a genetic case for developing therapies targeting coagulation factor XII, a promising and potentially safer antithrombotic drug target.
They used UK Biobank and All of Us data to show that people who have lost one copy of the F12 gene have lower VTE risk without an increased risk of bleeding.
Their study suggests that inhibiting factor XII would likely be a safe and effective approach for anticoagulation.”
Read the full article in Nature Communications.
Article: Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis
Authors: Amelia K. Haj, David S. Paul, Sean J. Jurgens, Harish Eswaran, Lu-Chen Weng, Justine Ryu, Alfonso Rodriguez Espada, Sharjeel Chaudhry, Louis M. Feingold, Kristen Burke, Satoshi Koyama, Xin Wang, Joyce Francis, Seung Hoan Choi, Nigel Mackman, Wolfgang Bergmeier, Alex Burgin, Joel T. Rämö, Patrick T. Ellinor, Steven P. Grover , Pavan K. Bendapudi
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 7, 2025, 04:20Nita Radhakrishnan to Present The First Indian Collaborative Data on Hemophilia from the WBDR Registry
-
Oct 6, 2025, 04:10EAHAD PT Committee Chair Ruth Elise Is Contributing to The Discussion On Joint Health and Mobility At EHC 2025
-
Oct 6, 2025, 03:44Caitlin Raymond: When We Talk About Plasma Exchange, Most Discussions Stop At What We’re Removing, But That’s Only Half The Story
-
Oct 6, 2025, 03:20Gianluigi Pasta On Cutting-Edge Cartilage Engineering for Bleeding Disorders Community at EHC 2025
-
Oct 5, 2025, 12:02Joseph Raffaele: Everyone Asks Me About Testosterone. Few Ask About DHEA
-
Oct 7, 2025, 03:56Nathan Connell: Interesting Data in The Management of HAC Has Been Published in Blood from Benoit Guillet and Colleagues
-
Oct 7, 2025, 03:40Nature Communications Study by Amelia Haj and Colleagues Identifies Factor XII as a Safer Target for Anticoagulation
-
Oct 7, 2025, 03:36Lisiena Hysenaj: Excited to Announce the Jeroen Roose Lab’s Latest Publication from Laila Karra Khalil
-
Oct 7, 2025, 03:06Ashkan Golshani: A Step Closer to Developing a Therapeutic Against Platelet-type von Willebrand Disease
-
Oct 6, 2025, 03:48New Insights On Pre-Existing AAV5 Abs in Haemophilia B Gene Therapy
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 7, 2025, 04:35Hema Tallman: During IPAW, We Honor The Unseen Heroes – Plasma Donors
-
Oct 7, 2025, 04:09Svenja Tatjana Barckhausen: Reducing Reliance on U.S. Plasma – Not Just for Europe, But for The World!
-
Oct 7, 2025, 03:58Louise Bannon: Don’t Wait Until You’re Diagnosed to Learn About Blood Clots
-
Oct 6, 2025, 03:57Mattia Galli - Nominated Among The Top 200 of 200,000 Leading Researchers Worldwide for The 2025 USERN Prize!
-
Oct 6, 2025, 03:46Marilena Vrana: I Want to Thank Grifols Deutschland for The Opportunity to Visit Their Premises and Biotest AG Manufacturing Facility in Dreieich